ClinicalTrials.gg
CompletedNCT04847557Updated Aug 20, 2025Results posted

A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial

A Phase 3 interventional study of Tirzepatide and Placebo in Obesity and Heart Failure With Preserved Ejection Fraction (HFpEF), sponsored by Eli Lilly and Company. Completed at 146 sites in 10 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-08-20.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
731
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 104 studies testing tirzepatide in Obesity — 60 open to participants now, 79 under way, 14 of them phase 3. Tirzepatide · Obesity.

Enrollment
10th of 104
731 · median 69
Started
2021
with 5 others
Phase 3
26 of 104
7 open now
Registered
8th of 104
by date
Lead sponsor
34 of 104
Eli Lilly and Company

Among the 104 studies testing tirzepatide in Obesity, this one is the 10th largest by enrollment, is one of 6 that started in 2021, is one of 26 in phase 3, and was the 8th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

60 of the 104 studies testing tirzepatide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

55 more — sign in →

By country, each count listing its studies:

All 60 open studies →

About tirzepatide

Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies testing tirzepatide in Obesity, or all of them as a file.
02

Study summary

The main purpose of this study is to assess the efficacy and safety of Tirzepatide (LY3298176) in participants with heart failure with preserved ejection fraction and obesity.

Read the detailed description

The study will continue until approximately 52 weeks after the last participant is randomized. The maximum duration of an individual's participation is estimated to be \~120 weeks and will depend on duration of study enrollment.

03

Conditions studied

  • Obesity
  • Heart Failure With Preserved Ejection Fraction (HFpEF)

Browse trials for

Keywords

  • Heart Failure with Preserved Ejection Fraction (HFpEF)
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of stable heart failure ( class II-IV) and (LVEF) ≥50%
  • Elevated NT-proBNP (N-terminal pro B-type natriuretic peptide) > 200 picogram/milliliter (pg/ml) for participants without atrial fibrillation (AF), or >600 pg/ml for participants with AF, Structural heart disease (Left atrial enlargement) or Elevated left ventricular filling pressure
  • Estimated (eGFR) \<70 milliliter (ml)/minute (min)/1.73m² at screening, or HF decompensation within 12 months of screening,
  • Stable dose of heart failure medications within 4 weeks of screening
  • (BMI) ≥30 kilograms per meter squared (kg/m²)
  • 6MWD 100-425 meters
  • KCCQ CSS ≤80

Exclusion criteria

Exclusion Criteria:

  • Have had a major cardiovascular event within the last 90 days of screening
  • Have had acute decompensated heart failure within 4 weeks of screening
  • Have non cardiac causes of functional impairment such as pulmonary arterial hypertension (PAH), severe (COPD), anemia, thyroid disease, musculoskeletal disease or orthopedic conditions
  • Presence of cardiac amyloidosis, cardiac accumulation disease, cardiomyopathy and severe valvular heart disease
  • ≥9.5% or uncontrolled diabetes
  • History of proliferative diabetic retinopathy or diabetic maculopathy
  • Have a history of pancreatitis
  • \<15 mL/min/1.73 m² or requiring dialysis at screening
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
731 participants (actual)

Study arms

  • Experimental
    Tirzepatide

    Participants received a starting dose of 2.5 milligrams (mg) tirzepatide administered subcutaneously (SC) once weekly (QW) and escalated by 2.5 mg every 4 weeks to a maximum of 15 mg QW or maximum tolerated dose (MTD) tolerated by the participant (5 mg QW or 10 mg QW).

    Drug: Tirzepatide

  • Placebo comparator
    Placebo

    Participants received placebo administered SC QW.

    Other: Placebo

Interventions

  • Administered SC

    Also known as: LY3298176

  • OtherPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS)

    The KCCQ is a 23-item, participant self-administered questionnaire that assesses impacts of heart failure "over the past 2 weeks" on the following 7 domains: * Physical Limitation (6) * Symptom Stability (1) * Symptom Frequency (4) * Symptom Burden (3) * Self-Efficacy (2) * Quality of Life (3) * Social Limitation (4) Each of the 23 individual items are answered on Likert scales of varying lengths (5, 6, or 7-point scales). KCCQ-CSS includes the symptom and physical limitation domains of the KCCQ. Scores are obtained by averaging the associated individual items and transforming the score to a 0 to 100 range. Higher scores indicate better health status. Least Square (LS) mean was determined using ANCOVA model with Baseline + HF Decompensation Within 12 Months of Screening + T2DM Status + Baseline BMI group (\<35, \>=35 kg/m2) + Treatment (Type III sum of squares) as variables .

    Time frame: Baseline, Week 52

  2. First Occurrence of the Composite Endpoint of Heart Failure (HF) Outcomes

    Clinical Endpoint Committe confirmed Occurrences of CV outcomes were reported here. HF outcomes consisted of cardiovascular death and HF events. The HF events were defined as worsening clinical symptoms or signs related to HF, which are meaningful to the participant and require intensification of treatment characterized by 1 or more of the following: * hospitalization for heart failure regardless of duration or treatment received * use of intravenous drug, usually an intravenous diuretic, but may include intravenous vasodilators or positive inotropic drugs, or * augmentation or increase in oral diuretic therapy.

    Time frame: Baseline Up To 160 weeks

Secondary outcomes

  1. Change From Baseline in Exercise Capacity as Measured by 6-Minute Walk Distance (6MWD)

    Participants performed an exercise capacity assessment using the 6-Minute Walk Test (6MWT) and the distance covered (6MWD) was assessed in meters. The 6MWT was performed indoors on a straight, flat, hard surface that is at least 30 meters in length. The greater distance walked meant better physical capacity. LS Mean was determined using ANCOVA model with Baseline + HF Decompensation Within 12 Months of Screening + T2DM Status + Baseline BMI group (\<35, \>=35 kg/m2) + Treatment (Type III sum of squares) as variables.

    Time frame: Baseline, Week 52

  2. Percent Change From Baseline in Body Weight

    Percent change in bodyweight was reported. LS mean was determined using ANCOVA model with Baseline + HF Decompensation Within 12 Months of Screening + T2DM Status + Baseline BMI group (\<35, \>=35 kg/m2) + Treatment (Type III sum of squares) as variables.

    Time frame: Baseline, Week 52

  3. Percent Change From Baseline in High-Sensitivity C-Reactive Protein (hsCRP)

    Percent change from baseline in hsCRP was reported. LS Mean was determined using ANCOVA model with log (actual measurement/baseline) = log (baseline) + HF decompensation within 12 months of screening + T2DM status + baseline BMI group (\<35, \>=35 kg/m2) + Treatment (Type III sum of squares) as variables.

    Time frame: Baseline, Week 52

  4. Win Percentage of the Hierarchical Composite Endpoint

    Hierarchical Composite Endpoint included time to all-cause death, number of HF events, time to first HF events, KCCQ-CSS, 6MWD. The winner was determined in each pair-wise comparison in the following order: * A delayed first occurrence of all-cause death * If the pair cannot be differentiated based on death, winner has fewer HF events * If the pair cannot be differentiated by number of HF events, winner has delayed time to occurrence of first HF event * If the pair still cannot be differentiated, winner has a more favorable category for change from baseline in 6MWD * If the pair still cannot be differentiated, winner has a more favorable category for change from baseline in KCCQ-CSS * Otherwise the pair will be recorded as tied. Reported unit is the total percent of "wins" for each treatment group from performing such a hierarchical comparison across stratification factors in the study.

    Time frame: Baseline Up To 160 Weeks

  5. Percentage of Participants With New York Heart Association (NYHA) Class Change

    Percentage of participants with NYHA class change at Week 52 was reported.

    Time frame: Week 52

  6. Number of Participants With Time to All-Cause Death

    All-cause mortality is death due to any cause. Number of participants with time to all-cause mortality are presented.

    Time frame: Baseline Up To 160 Weeks

  7. Number of Participants With Time to First Occurrence of HF Events

    Number of participants with time to first occurrence of HF events are reported.

    Time frame: Baseline Up To 160 Weeks

  8. Number of HF Events and All-Cause Death

    Number of HF events and all-cause death are reported.

    Time frame: Baseline Up To 160 Weeks.

  9. Number of Recurrent HF Events

    Number of recurrent HF events were reported.

    Time frame: Baseline Up To 160 Weeks.

07

Results

Posted Aug 20, 2025

Participant flow

Participant flow — Overall Study
MilestoneTirzepatide - MTDPlacebo
Started364367
Received at least one dose of study drug364367
Completed332331
Not completed3236
Withdrew: Adverse event10
Withdrew: Death1915
Withdrew: Lost to follow-up36
Withdrew: Physician decision10
Withdrew: Protocol violation01
Withdrew: Withdrawal by subject814

Outcome measures

PrimaryChange From Baseline in the Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS)

The KCCQ is a 23-item, participant self-administered questionnaire that assesses impacts of heart failure "over the past 2 weeks" on the following 7 domains: * Physical Limitation (6) * Symptom Stability (1) * Symptom Frequency (4) * Symptom Burden (3) * Self-Efficacy (2) * Quality of Life (3) * Social Limitation (4) Each of the 23 individual items are answered on Likert scales of varying lengths (5, 6, or 7-point scales). KCCQ-CSS includes the symptom and physical limitation domains of the KCCQ. Scores are obtained by averaging the associated individual items and transforming the score to a 0 to 100 range. Higher scores indicate better health status. Least Square (LS) mean was determined using ANCOVA model with Baseline + HF Decompensation Within 12 Months of Screening + T2DM Status + Baseline BMI group (\<35, \>=35 kg/m2) + Treatment (Type III sum of squares) as variables .

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · Score on a scale
Change From Baseline in the Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS)
Score on a scaleTirzepatide - MTDPlacebo
Change From Baseline in the Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS)19.51 ± 1.2412.68 ± 1.25
Statistical analysis
  • Tirzepatide - MTD vs Placebo · Stratified Wilcoxon · p = <0.001 · Median difference (net): 6.9 · 95% CI 3.3 to 10.6The Hodges-Lehmann estimate for the median difference and 95% CIs was reported.
PrimaryFirst Occurrence of the Composite Endpoint of Heart Failure (HF) Outcomes

Clinical Endpoint Committe confirmed Occurrences of CV outcomes were reported here. HF outcomes consisted of cardiovascular death and HF events. The HF events were defined as worsening clinical symptoms or signs related to HF, which are meaningful to the participant and require intensification of treatment characterized by 1 or more of the following: * hospitalization for heart failure regardless of duration or treatment received * use of intravenous drug, usually an intravenous diuretic, but may include intravenous vasodilators or positive inotropic drugs, or * augmentation or increase in oral diuretic therapy.

Time frame:
Baseline Up To 160 weeks
Reported as:
Number · Number of events
First Occurrence of the Composite Endpoint of Heart Failure (HF) Outcomes
Number of eventsTirzepatide - MTDPlacebo
First Occurrence of the Composite Endpoint of Heart Failure (HF) Outcomes3656
Statistical analysis
  • Tirzepatide - MTD vs Placebo · Regression, Cox · p = 0.026 · Hazard ratio (hr): 0.62 · 95% CI 0.41 to 0.95
SecondaryChange From Baseline in Exercise Capacity as Measured by 6-Minute Walk Distance (6MWD)

Participants performed an exercise capacity assessment using the 6-Minute Walk Test (6MWT) and the distance covered (6MWD) was assessed in meters. The 6MWT was performed indoors on a straight, flat, hard surface that is at least 30 meters in length. The greater distance walked meant better physical capacity. LS Mean was determined using ANCOVA model with Baseline + HF Decompensation Within 12 Months of Screening + T2DM Status + Baseline BMI group (\<35, \>=35 kg/m2) + Treatment (Type III sum of squares) as variables.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · meters
Change From Baseline in Exercise Capacity as Measured by 6-Minute Walk Distance (6MWD)
metersTirzepatide - MTDPlacebo
Change From Baseline in Exercise Capacity as Measured by 6-Minute Walk Distance (6MWD)26.04 ± 3.8110.10 ± 3.94
Statistical analysis
  • Tirzepatide - MTD vs Placebo · Stratified Wilcoxon · p = <0.001 · Median difference (net): 18.3 · 95% CI 9.9 to 26.7The Hodges-Lehmann estimate for the median difference and 95% CIs was reported.
SecondaryPercent Change From Baseline in Body Weight

Percent change in bodyweight was reported. LS mean was determined using ANCOVA model with Baseline + HF Decompensation Within 12 Months of Screening + T2DM Status + Baseline BMI group (\<35, \>=35 kg/m2) + Treatment (Type III sum of squares) as variables.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Body Weight
Percent changeTirzepatide - MTDPlacebo
Percent Change From Baseline in Body Weight-13.85 ± 0.43-2.24 ± 0.46
Statistical analysis
  • Tirzepatide - MTD vs Placebo · ANCOVA · p = <0.001 · Ls mean difference: -11.62 · 95% CI -12.85 to -10.38
SecondaryPercent Change From Baseline in High-Sensitivity C-Reactive Protein (hsCRP)

Percent change from baseline in hsCRP was reported. LS Mean was determined using ANCOVA model with log (actual measurement/baseline) = log (baseline) + HF decompensation within 12 months of screening + T2DM status + baseline BMI group (\<35, \>=35 kg/m2) + Treatment (Type III sum of squares) as variables.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in High-Sensitivity C-Reactive Protein (hsCRP)
Percent changeTirzepatide - MTDPlacebo
Percent Change From Baseline in High-Sensitivity C-Reactive Protein (hsCRP)-38.76 ± 4.47-5.88 ± 5.25
Statistical analysis
  • Tirzepatide - MTD vs Placebo · ANCOVA · p = <0.001 · Ls mean difference: -34.91 · 95% CI -45.60 to -22.17
SecondaryWin Percentage of the Hierarchical Composite Endpoint

Hierarchical Composite Endpoint included time to all-cause death, number of HF events, time to first HF events, KCCQ-CSS, 6MWD. The winner was determined in each pair-wise comparison in the following order: * A delayed first occurrence of all-cause death * If the pair cannot be differentiated based on death, winner has fewer HF events * If the pair cannot be differentiated by number of HF events, winner has delayed time to occurrence of first HF event * If the pair still cannot be differentiated, winner has a more favorable category for change from baseline in 6MWD * If the pair still cannot be differentiated, winner has a more favorable category for change from baseline in KCCQ-CSS * Otherwise the pair will be recorded as tied. Reported unit is the total percent of "wins" for each treatment group from performing such a hierarchical comparison across stratification factors in the study.

Time frame:
Baseline Up To 160 Weeks
Reported as:
Number · Win percentage
Win Percentage of the Hierarchical Composite Endpoint
Win percentageTirzepatide - MTDPlacebo
Win Percentage of the Hierarchical Composite Endpoint57.9035.43
Statistical analysis
  • Tirzepatide - MTD vs Placebo · Win ratio: 1.63 · 95% CI 1.17 to 2.28The win ratio was reported as the measure of treatment effect based on the principle that each participant is compared with every other participant within each stratum in a pair-wise manner that proceeds in a hierarchical fashion.
SecondaryPercentage of Participants With New York Heart Association (NYHA) Class Change

Percentage of participants with NYHA class change at Week 52 was reported.

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With New York Heart Association (NYHA) Class Change
Percentage of participantsTirzepatide - MTDPlacebo
Percentage of Participants With New York Heart Association (NYHA) Class Change33.2720.39
Statistical analysis
  • Tirzepatide - MTD vs Placebo · Odds ratio (or): 2.28 · 95% CI 1.53 to 3.40
SecondaryNumber of Participants With Time to All-Cause Death

All-cause mortality is death due to any cause. Number of participants with time to all-cause mortality are presented.

Time frame:
Baseline Up To 160 Weeks
Reported as:
Count of participants · Participants
Number of Participants With Time to All-Cause Death
ParticipantsTirzepatide - MTDPlacebo
Number of Participants With Time to All-Cause Death1915
Statistical analysis
  • Tirzepatide - MTD vs Placebo · Hazard ratio (hr): 1.245 · 95% CI 0.633 to 2.452
SecondaryNumber of Participants With Time to First Occurrence of HF Events

Number of participants with time to first occurrence of HF events are reported.

Time frame:
Baseline Up To 160 Weeks
Reported as:
Count of participants · Participants
Number of Participants With Time to First Occurrence of HF Events
ParticipantsTirzepatide - MTDPlacebo
Number of Participants With Time to First Occurrence of HF Events2952
Statistical analysis
  • Tirzepatide - MTD vs Placebo · Hazard ratio (hr): 0.539 · 95% CI 0.342 to 0.850
SecondaryNumber of HF Events and All-Cause Death

Number of HF events and all-cause death are reported.

Time frame:
Baseline Up To 160 Weeks.
Reported as:
Number · Events
Number of HF Events and All-Cause Death
EventsTirzepatide - MTDPlacebo
Number of HF Events and All-Cause Death6182
Statistical analysis
  • Tirzepatide - MTD vs Placebo · Rate ratio: 0.72 · 95% CI 0.46 to 1.14
SecondaryNumber of Recurrent HF Events

Number of recurrent HF events were reported.

Time frame:
Baseline Up To 160 Weeks.
Reported as:
Number · Events
Number of Recurrent HF Events
EventsTirzepatide - MTDPlacebo
Number of Recurrent HF Events4468
Statistical analysis
  • Tirzepatide - MTD vs Placebo · Rate ratio: 0.62 · 95% CI 0.37 to 1.05

Adverse events

Collected over Baseline Up To 162 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tirzepatide - MTD19/364 (5.2%)96/364 (26.4%)221/364 (60.7%)
Placebo15/367 (4.1%)94/367 (25.6%)137/367 (37.3%)
Most frequent serious events
Showing 10 of 186
Most frequent serious events
EventTirzepatide - MTDPlacebo
Cardiac failureCardiac disorders12/36418/367
Cardiac failure congestiveCardiac disorders3/36412/367
Atrial fibrillationCardiac disorders7/3643/367
Acute myocardial infarctionCardiac disorders6/3642/367
Cholecystitis acuteHepatobiliary disorders6/3644/367
CellulitisInfections and infestations0/3646/367
PneumoniaInfections and infestations5/3646/367
Urinary tract infectionInfections and infestations5/3641/367
Acute kidney injuryRenal and urinary disorders5/3643/367
AnaemiaBlood and lymphatic system disorders1/3645/367
Most frequent other events
Showing 10 of 12
Most frequent other events
EventTirzepatide - MTDPlacebo
DiarrhoeaGastrointestinal disorders65/36423/367
NauseaGastrointestinal disorders62/36423/367
ConstipationGastrointestinal disorders54/36422/367
Covid-19Infections and infestations33/36441/367
VomitingGastrointestinal disorders38/3647/367
Decreased appetiteMetabolism and nutrition disorders38/3646/367
DizzinessNervous system disorders34/36418/367
Urinary tract infectionInfections and infestations31/36422/367
DyspepsiaGastrointestinal disorders23/3648/367
HypotensionVascular disorders22/36410/367

Baseline characteristics

All participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Tirzepatide - MTDPlaceboTotal
Mean65.50 ± 10.5365.00 ± 10.8765.20 ± 10.70
Sex: Female, Male
Sex: Female, Male(Participants)Tirzepatide - MTDPlaceboTotal
Female200193393
Male164174338
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Tirzepatide - MTDPlaceboTotal
Hispanic or Latino195205400
Not Hispanic or Latino164159323
Unknown or Not Reported538
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Tirzepatide - MTDPlaceboTotal
American Indian or Alaska Native242347
Asian5873131
Native Hawaiian or Other Pacific Islander213
Black or African American221436
White256256512
More than one race202
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Tirzepatide - MTDPlaceboTotal
Argentina101103204
Brazil5154105
China253055
India91120
Israel172138
Mexico414081
Russia13821
Taiwan243256
United States8368151
08

Study locations

146 sites
  • Heart Center Research
    Huntsville, Alabama 35801, United States
  • Westside Medical Associates of Los Angeles
    Beverly Hills, California 90211, United States
  • Valley Clinical Trials, Inc.
    Covina, California 91723, United States
  • Amicis Research Center
    Granada Hills, California 91344, United States
  • University of California San Diego - La Jolla
    La Jolla, California 92037, United States
  • Valley Clinical Trials, Inc.
    Northridge, California 91325, United States
  • The Lundquist Institute
    Torrance, California 90502, United States
  • South Denver Cardiology Associates
    Littleton, Colorado 80120, United States
  • Cardiology Associates of Fairfield County, P.C.
    Stamford, Connecticut 06905, United States
  • Excel Medical Clinical Trials
    Boca Raton, Florida 33434, United States
  • Clearwater Cardiovascular & Interventional Consultants M.D., P.A.
    Clearwater, Florida 33756, United States
  • Clearwater Cardiovascular & Interventional Consultants M.D., P.A.
    Largo, Florida 33777, United States
  • Infinite Clinical Research
    Miami, Florida 33133, United States
  • Ocala Caridovascular Research
    Ocala, Florida 34471, United States
  • Clearwater Cardiovascular & Interventional Consultants M.D., P.A.
    Safety Harbor, Florida 34695, United States
  • East Coast Institute for Research - St. Augustine
    Saint Augustine, Florida 32086, United States
  • Morehouse School Of Medicine
    Atlanta, Georgia 30310, United States
  • St. Luke's Boise Medical Center
    Boise, Idaho 83712, United States
  • Northwest Heart Clinical Research
    Arlington Heights, Illinois 60005, United States
  • Methodist Medical Center of Illinois
    Peoria, Illinois 61636, United States
  • Cardiovascular Research of Northwest Indiana
    Munster, Indiana 46321, United States
  • Midwest Heart & Vascular Specialists
    Overland Park, Kansas 66211, United States
  • Grace Research - Bossier
    Bossier City, Louisiana 71111, United States
  • The Heart Clinic - Hammond
    Hammond, Louisiana 70403, United States
  • Grace Research - Shreveport
    Shreveport, Louisiana 71105, United States
  • Maryland Cardiovascular Specialists
    Baltimore, Maryland 21229, United States
  • McLaren Bay Region
    Bay City, Michigan 48708, United States
  • St. Louis Heart and Vascular, P.C.
    St Louis, Missouri 63136, United States
  • Palm Research Center Tenaya
    Las Vegas, Nevada 89128, United States
  • The Heart House
    Haddon Heights, New Jersey 08035, United States
  • Lovelace Medical Center
    Albuquerque, New Mexico 87102, United States
  • Erie County Medical Center
    Buffalo, New York 14215, United States
  • Rochester General Hospital
    Rochester, New York 14621, United States
  • Saratoga Cardiology Associates
    Saratoga Springs, New York 12866, United States
  • Stony Brook University
    Stony Brook, New York 11794, United States
  • OnSite Clinical Solutions
    Charlotte, North Carolina 28277, United States
  • Aultman Hospital Research
    Canton, Ohio 44710, United States
  • Rama Research
    Marion, Ohio 43302, United States
  • Hightower Clinical Trial Services
    Oklahoma City, Oklahoma 73102, United States
  • Hillsboro Cardiology
    Hillsboro, Oregon 97123, United States
  • Capital Area Research, LLC
    Camp Hill, Pennsylvania 17011, United States
  • Doylestown Hospital
    Doylestown, Pennsylvania 18901, United States
  • UPMC Clinical Trials
    Pittsburgh, Pennsylvania 15213, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Monument Health Rapid City Hospital
    Rapid City, South Dakota 57701, United States
  • The Stern Cardiovascular Foundation
    Germantown, Tennessee 38138, United States
  • Apex Research Foundation
    Jackson, Tennessee 38301, United States
  • DiscoveResearch
    Beaumont, Texas 77701, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75390, United States
  • North Dallas Research Associates
    McKinney, Texas 75069, United States
  • Sherman Clinical Research
    Sherman, Texas 75092, United States
  • Northwest Houston Heart Center
    Tomball, Texas 77375, United States
  • Intermountain Medical Center
    Murray, Utah 84107, United States
  • MultiCare Good Samaritan Hospital
    Puyallup, Washington 98372, United States
  • DIM Clínica Privada
    Ramos Mejía, Buenos Aires 1704, Argentina
  • Go Centro Medico San Nicolás
    San Nicolás de los Arroyos, Buenos Aires 2900, Argentina
  • Instituto Médico Especializado (IME)
    Buenos Aires, Buenos Aires F.D. 1405, Argentina
  • Mautalen Salud e Investigación
    Buenos Aires, Buenos Aires F.D. C1128AAF, Argentina
  • Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada
    Buenos Aires, Buenos Aires F.D. C1425AGC, Argentina
  • Centro de Investigaciones Metabólicas (CINME)
    Ciudad Autónoma de Buenos Aire, Buenos Air C1027AAP, Argentina
  • CIPREC
    Buenos Aires, Ciudad Autónoma de Buenos Aire C1061AAS, Argentina
  • Instituto Médico Río Cuarto
    Río Cuarto, Córdoba Province 5800, Argentina
  • Instituto de Investigaciones Clinicas Rosario
    Rosario, Santa Fe Province S2000CVD, Argentina
  • CEMEDIC
    Buenos Aires, 1407, Argentina
  • Fundación Respirar
    Buenos Aires, 1426, Argentina
  • Instituto de Cardiología "Juana F. Cabral"
    Corrientes, 3400, Argentina
  • Centro de Investigaciones Clinicas Instituto del Corazon (CICIC)
    Córdoba, X5002HWE, Argentina
  • Hospital de Alta Complejidad "Pte. Juan Domingo Perón"
    Formosa, 3600, Argentina
  • Centro Cardiovascular Salta
    Salta, 4406, Argentina
  • Instituto Cardiovascular San Luis
    San Luis, 5700, Argentina
  • Centro de Investigaciones Clinicas del Litoral
    Santa Fe, 3000, Argentina
  • Universidade Federal de Goias
    Goiânia, Goiás 74605-020, Brazil
  • Hospital Angelina Caron
    Campina Grande do Sul, Paraná 83430-000, Brazil
  • Centro de Pesquisa Clinica do Coracao
    Aracaju, Sergipe 49055-530, Brazil
  • Centro de Pesquisa Sao Lucas
    Campinas, São Paulo 13034-685, Brazil
  • Instituto de Pesquisa clinica de Campinas
    Campinas, São Paulo 13060-080, Brazil
  • Loema Instituto de Pesquisa Clinica
    Campinas, São Paulo 13092133, Brazil
  • CAPED Centro Avancado Pesquisa e Diagnostica
    Ribeirão Preto, São Paulo 14026-900, Brazil
  • Pesquisare Saude
    Santo André, São Paulo 09080-110, Brazil
  • Fundação Faculdade Regional de Medicina de São José do Rio Preto
    São José do Rio Preto, São Paulo 15090000, Brazil
  • IBPClin - Instituto Brasil de Pesquisa Clínica
    Rio de Janeiro, 22241-180, Brazil
  • CEPIC - Centro Paulista de Investigação Clínica
    São Paulo, 04266-010, Brazil
  • Peking University First Hospital
    Beijing, Beijing Municipality 100034, China
  • Beijing Friendship Hospital
    Beijing, Beijing Municipality 100050, China
  • Lanzhou university second hospital
    Lanzhou, Gansu 730030, China
  • The First Hospital of Harbin Medical University
    Harbin, Heilongjiang 150001, China
  • Wuhan University Medical College - Hubei Zhongshan Hospital
    Wuhan, Hubei 430000, China
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan 410013, China
  • 1st Hospital affiliate to Baotou medical college
    Baotou, Inner Mongolia 014010, China
  • Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School
    Nanjing, Jiangsu 210000, China
  • The Second Affiliated Hospital of Nanjing Medical University
    Nanjing, Jiangsu 210011, China
  • The Second Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330006, China
  • Jiangxi Pingxiang People's Hospital
    Pingxiang, Jiangxi 337055, China
  • Jilin Province People's Hospital
    Changchun, Jilin 130021, China
  • China-Japan Union Hospital
    Changchun, Jilin 130033, China
  • The first affiliated hospital of dalian medical university
    Dalian, Liaoning 116000, China
  • The People's Hospital of Liaoning Province
    Shenyang, Liaoning 110000, China
  • The First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shaanxi 710061, China
  • Jinan Central Hospital
    Jinan, Shandong 250013, China
  • Zhongshan Hospital,Fudan University
    Shanghai, Shanghai Municipality 200032, China

Showing the first 100 of 146 sites across 10 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Borlaug BA, Zile MR, Kramer CM, Litwin SE, Ye W, Ou Y, Hurt K, Murakami M, Packer M; SUMMIT Trial Group. Effects of Tirzepatide in Obesity-Related HFpEF by Sex: A Prespecified Secondary Analysis From the SUMMIT Trial. JACC Heart Fail. 2026 Jul 7:103218. doi: 10.1016/j.jchf.2026.103218. Online ahead of print. PubMed 42417681 ↗
  • Packer M, Zile MR, Kramer CM, DiMaria JM, Baum SJ, Litwin SE, Murakami M, Zhou C, Ou Y, Koeneman L, Borlaug BA; SUMMIT Trial Study Group. Influence of Type 2 Diabetes on the Effects of Tirzepatide in Patients With Heart Failure and a Preserved Ejection Fraction With Obesity: A Prespecified Stratification-Based Analysis. J Am Coll Cardiol. 2025 Sep 9;86(10):696-707. doi: 10.1016/j.jacc.2025.06.058. PubMed 40903131 ↗
  • Borlaug BA, Zile MR, Kramer CM, Ye W, Ou Y, Hurt K, Murakami M, Packer M; SUMMIT Trial Study Group. Impact of Body Mass Index, Central Adiposity, and Weight Loss on the Benefits of Tirzepatide in HFpEF: The SUMMIT Trial. J Am Coll Cardiol. 2025 Jul 29;86(4):242-255. doi: 10.1016/j.jacc.2025.04.059. PubMed 40701669 ↗
  • Packer M, Zile MR, Kramer CM, Murakami M, Ou Y, Borlaug BA; SUMMIT Trial Study Group. Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity: The SUMMIT Trial. J Am Coll Cardiol. 2025 May 13;85(18):1721-1735. doi: 10.1016/j.jacc.2025.03.009. Epub 2025 Mar 31. PubMed 40162940 ↗
  • Kramer CM, Borlaug BA, Zile MR, Ruff D, DiMaria JM, Menon V, Ou Y, Zarante AM, Hurt KC, Murakami M, Packer M; SUMMIT Trial Study Group. Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy. J Am Coll Cardiol. 2025 Feb 25;85(7):699-706. doi: 10.1016/j.jacc.2024.11.001. Epub 2024 Nov 18. PubMed 39566869 ↗
  • Zile MR, Borlaug BA, Kramer CM, Baum SJ, Litwin SE, Menon V, Ou Y, Weerakkody GJ, Hurt KC, Kanu C, Murakami M, Packer M; SUMMIT Trial Study Group. Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity. Circulation. 2025 Mar 11;151(10):656-668. doi: 10.1161/CIRCULATIONAHA.124.072679. Epub 2024 Nov 18. PubMed 39556714 ↗
  • Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, Ge J, Weerakkody GJ, Ou Y, Bunck MC, Hurt KC, Murakami M, Borlaug BA; SUMMIT Trial Study Group. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2025 Jan 30;392(5):427-437. doi: 10.1056/NEJMoa2410027. Epub 2024 Nov 16. PubMed 39555826 ↗
  • Borlaug BA, Zile MR, Kramer CM, Baum SJ, Hurt K, Litwin SE, Murakami M, Ou Y, Upadhyay N, Packer M. Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial. Nat Med. 2025 Feb;31(2):544-551. doi: 10.1038/s41591-024-03374-z. Epub 2024 Nov 17. PubMed 39551891 ↗
  • Reese-Petersen AL, Holm Nielsen S, Bulow Sand JM, Schattenberg JM, Bugianesi E, Karsdal MA. The sclerotic component of metabolic syndrome: Fibroblast activities may be the central common denominator driving organ function loss and death. Diabetes Obes Metab. 2024 Jul;26(7):2554-2566. doi: 10.1111/dom.15615. Epub 2024 May 3. PubMed 38699780 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Jul 2024, 38 months.

Results were first posted in Aug 2025, 1 year 1 month after primary completion.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 38 months is above that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2021
First posted
Apr 19, 2021
StartActual
Apr 20, 2021
Primary completionActual
Jul 2, 2024
CompletionActual
Jul 2, 2024
Results first posted
Aug 20, 2025
Last update
Aug 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04847557
Responsible party
Sponsor
First posted
Apr 19, 2021
Start date
Apr 20, 2021
Primary completion
Jul 2, 2024
Completion
Jul 2, 2024
Results posted
Aug 20, 2025
Last update
Aug 20, 2025

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion